6388 related articles for article (PubMed ID: 14621568)
1. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
2. [Treatment outcomes of multidrug-resistant tuberculosis--comparison between success and failure cases].
Shigetoh E; Murakami I; Yokosaki Y; Kurimoto N
Kekkaku; 2001 Dec; 76(12):723-8. PubMed ID: 11806128
[TBL] [Abstract][Full Text] [Related]
3. [Agranulocytosis due to anti-tuberculosis drugs including isoniazid (INH) and rifampicin (RFP)--a report of four cases and review of the literature].
Shishido Y; Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Komatsu H; Yotsumoto H
Kekkaku; 2003 Nov; 78(11):683-9. PubMed ID: 14672045
[TBL] [Abstract][Full Text] [Related]
4. [Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study].
Yoshiyama T; Ogata H; Ito K; Aono A; Wada M
Kekkaku; 2007 Feb; 82(2):95-101. PubMed ID: 17373318
[TBL] [Abstract][Full Text] [Related]
5. [Effects of two treatment regimens for drug-resistant tuberculosis in tuberculosis control project areas: a comparative study].
Li L; Zheng SH; Chu NH; Xie YG; Yang YZ; Li Q; Wang XM; Yan XL; Tan WG; Miao ZP; Duanmu HJ
Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3387-91. PubMed ID: 19159566
[TBL] [Abstract][Full Text] [Related]
6. [Retreatment of pulmonary tuberculosis--duration of chemotherapy].
Wada M; Seita A; Mori T; Ogata H; Sugie T; Sugita H
Kekkaku; 1993 Jul; 68(7):469-78. PubMed ID: 8361115
[TBL] [Abstract][Full Text] [Related]
7. [Six-month short course chemotherapy containing pyrazinamide for initial treatment of pulmonary tuberculosis].
Wada M; Yosiyama T; Yosikawa M; Ogata H; Sugie T; Nakasono T; Sugita H
Kekkaku; 1994 Nov; 69(11):671-80. PubMed ID: 7837720
[TBL] [Abstract][Full Text] [Related]
8. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
[TBL] [Abstract][Full Text] [Related]
9. [The short-term and long-term treatment outcomes in patients with pulmonary tuberculosis positive for drug-resistant and sensitive strains].
Han JP; Sun SL; Li RZ; Zhang FS; Wang SC; Cheng J; Deng YF; Wang Y; Yu CB
Zhonghua Jie He He Hu Xi Za Zhi; 2003 Feb; 26(2):70-3. PubMed ID: 12783654
[TBL] [Abstract][Full Text] [Related]
10. [A case of drug-resistant pulmonary tuberculosis treated successfully following disappearance of rifampicin resistance after 17 years' chemotherapy].
Shigeto E; Murakami I; Yokosaki Y
Kekkaku; 2001 Apr; 76(4):379-83. PubMed ID: 11398329
[TBL] [Abstract][Full Text] [Related]
11. [Attributable factors to the emergence of multidrug-resistant Mycobacterium tuberculosis based on the observation of consecutive drug resistance test results].
Fujino T; Hasegawa N; Satou R; Komatsu H; Kawada K
Kekkaku; 1998 Jul; 73(7):471-6. PubMed ID: 9739579
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
13. Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy.
Migliori GB; Espinal M; Danilova ID; Punga VV; Grzemska M; Raviglione MC
Int J Tuberc Lung Dis; 2002 Oct; 6(10):858-64. PubMed ID: 12365571
[TBL] [Abstract][Full Text] [Related]
14. [Risk of acquisition of RFP resistance out of INH resistant RFP susceptible tuberculosis].
Yoshiyama T; Ito K; Ogata H; Aono A; Wada M
Kekkaku; 2005 Jan; 80(1):9-14. PubMed ID: 15839057
[TBL] [Abstract][Full Text] [Related]
15. Outcome of chemotherapy in 107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin.
Park SK; Kim CT; Song SD
Int J Tuberc Lung Dis; 1998 Nov; 2(11):877-84. PubMed ID: 9848607
[TBL] [Abstract][Full Text] [Related]
16. [Anti-tuberculosis chemotherapy].
Wada M
Kekkaku; 2007 Oct; 82(10):771-81. PubMed ID: 18018601
[TBL] [Abstract][Full Text] [Related]
17. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
Nolan CM; Goldberg SV
Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
[TBL] [Abstract][Full Text] [Related]
18. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
Int J Tuberc Lung Dis; 1997 Dec; 1(6):509-17. PubMed ID: 9487448
[TBL] [Abstract][Full Text] [Related]
19. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
[TBL] [Abstract][Full Text] [Related]
20. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
